Entera Bio Ltd (NASDAQ: ENTX) is a clinical-stage biopharmaceutical company developing oral delivery therapies for large-molecule drugs, with its pipeline centered on product candidates EB613, EB612, and OXM. The company generates no product revenue. Funding comes from equity issuances, including the Leerink ATM Program, and potential licensing or collaboration arrangements involving its N-Tab oral drug delivery platform. As of the 10-K filed 2026-03-27, Entera had not commercialized any product and carried net cash used in operating activities of $7.4 million for the year ended December 31, 2025, versus $6.8 million for the year ended December 31, 2024. Research and development expenses totaled $6.0 million in FY2025, up from $4.5 million in FY2024, with the largest external spend on EB613 at $2.1 million in FY2025. A collaboration with OPKO on OXM contributed $437,000 in internal and external R&D costs in FY2025. Leadership includes CEO Miranda Toledano, Chief of R&D Gregory Burshtein, and COO Hillel Galitzer. The company operates under Israeli and U.S. regulatory jurisdictions.

Revenue model

No commercial revenue as of FY2025. Financing is sourced from equity sales via the Leerink ATM Program and potential future licensing or collaboration agreements tied to the N-Tab oral drug delivery platform.

Products and services

Pipeline includes EB613 (oral parathyroid hormone candidate), EB612, and OXM (developed in collaboration with OPKO). The N-Tab platform is the underlying oral delivery technology available for external licensing and partnerships.

Customers and end markets

No commercial customers as of FY2025. End market is pharmaceutical and biopharmaceutical drug development, with potential patients in osteoporosis or related bone/metabolic disease indications implied by the pipeline, though the filing does not specify approved indications.

Value-chain role

Drug developer and platform licensor. Entera conducts preclinical and clinical development internally and through third-party CROs, and relies on contract manufacturers for clinical supplies. It does not manufacture or commercialize products.

Geographic exposure

Operations span the United States, Israel, the United Kingdom, and the EU, based on data privacy and regulatory jurisdictions cited in the 10-K filed 2026-03-27.

Source: SEC 10-K, filed 2026-03-27

Industry: Biological Products, (No Diagnostic Substances) Peers: Chemomab Therapeutics Ltd Collplant Biotechnologies Ltd Protalix Biotherapeutics Inc Evogene Ltd